The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.

  • JackbyDev@programming.devEnglish
    8·
    10 hours ago

    Don’t give me that ‘hindsight is 20/20’, it was the first thought I had when I heard about this.

    ‘How are they going to monetize this?’

    The tests weren’t free.

    • msage@programming.dev
      31·
      10 hours ago

      So what are they going to do after?

      You won’t get tested twice, they still need to pay for existing. After they test everyone, how are they going to keep it up?

      Unless they take more money from you, they will sell your data to someone else.

      Insurance companies? Advertisers? Those things provide value for bad actors more than for you.